Physician profile
Richard Wasserman
NPI 1659333615
$53,296.65
in general payments reported to CMS, 2019-2025
51 companies · $4,175 in 2025
The $4,175 reported for 2025 was more than what 91% of Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) providers received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $11K · 2021: $9,920 · 2022: $1,012 · 2023: $950 · 2024: $618 · 2025: $4,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,500 · Food and Beverage: $2,119 · Education: $74.99 · Gift: $49.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,500.00 |
| Food and Beverage | $2,118.62 |
| Education | $74.99 |
| Gift | $49.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $43,499.32 | 2019-2022 | |
| Gc Biopharma USA, INC. | $3,500.00 | 2025 | Alyglo |
| Coloplast Corp | $1,002.10 | 2019-2024 | Sensura |
| Medtronic USA, INC. | $959.37 | 2019-2020 | |
| Astellas Pharma US INC | $693.27 | 2019-2025 | Veozah, Myrbetriq |
| Caldera Medical, INC | $539.32 | 2019-2023 | Desara |
| Medtronic, INC. | $410.80 | 2021-2023 | Interstim |
| Sumitomo Pharma America, INC. | $344.43 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $258.40 | 2023-2025 | Botox |
| Boston Scientific Corporation | $241.38 | 2019-2025 | General - Erectile Dysfunction |
| Axonics, INC. | $204.21 | 2021-2023 | Bulkamid, Axonics |
| Merck Sharp & Dohme LLC | $148.80 | 2019-2023 | Keytruda, Lynparza |
| Minerva Surgical, INC | $98.16 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $97.50 | 2021-2025 | Exparel |
| Femselect INC. | $97.09 | 2023 | Enplace |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.